Abstract: SA-OR99
Associations of APOL1 Biallelic and Monoallelic Kidney Disease Variants with CKDs in West Africans: H3Africa KDRN Study
Session Information
- Late-Breaking Science Orals - 2
October 26, 2024 | Location: Room 6C, Convention Center
Abstract Time: 04:50 PM - 05:00 PM
Category: Genetic Diseases of the Kidneys
- 1202 Genetic Diseases of the Kidneys: Non-Cystic
Authors
- Gbadegesin, Rasheed A., Duke University School of Medicine, Durham, North Carolina, United States
- Ulasi, Ifeoma I., Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
- Raji, Yemi R., University of Ibadan, Ibadan, Oyo, Nigeria
- Mamven, Manmak, University of Abuja, Abuja, Federal Capital Territory, Nigeria
- Adeyemo, Adebowale A., National Human Genome Research Institute, Bethesda, Maryland, United States
- Ilori, Titilayo O., Boston University, Boston, Massachusetts, United States
- Solarin, Adaobi, Lagos State University, Ojo, Lagos, Nigeria
- Kimmel, Paul L., National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, United States
- Brosius, Frank C., University of Arizona, Tucson, Arizona, United States
- Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
- Hodgin, Jeffrey B., University of Michigan, Ann Arbor, Michigan, United States
- Pollak, Martin, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Freedman, Barry I., Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
- Williams, Winfred W., Massachusetts General Hospital, Boston, Massachusetts, United States
- Parekh, Rulan S., Women's College Hospital, Toronto, Ontario, Canada
- Adu, Dwomoa, University of Ghana Medical School, Accra, Greater Accra, Ghana
- Ojo, Akinlolu, The University of Kansas Medical Center, Kansas City, Kansas, United States
Group or Team Name
- The H3Africa Kidney Disease Research Network
Background
Background: Apolipoprotein L1 gene (APOL1) variants are risk factors for chronic kidney disease (CKD) among African Americans (AA). Data are sparse on the genetic epidemiology and clinical association of APOL1 variants with CKD in West Africans, a major group among the AA population.
Methods
The Human Health and Heredity in Africa (H3Africa) Kidney Disease Research Network studied 8,355 participants from Ghana and Nigeria: 4,712 participants with CKD stages 2-5, 866 participants with biopsy proven glomerular diseases, and 2777 controls (eGFR ≥90 ml/min/1.73m2 and no proteinuria). The association of CKD with high-risk carriers (two APOL1 alleles) and low-risk carriers (<2 APOL1 alleles) was determined by fitting logistic regression models controlling for covariates, including clinical site, age, and sex.
Results
Monoallelic and biallelic APOL1 variant prevalence were 43.0% and 29.7%, respectively. Compared with low-risk carriers, the adjusted odds of CKD and focal segmental glomerulosclerosis (FSGS) among high-risk carriers were 1.25 (95%CI: 1.11-1.40) and 1.84 (95%CI 1.30-2.61), respectively. Compared with those with no APOL1 variant (G0/G0), persons with one APOL1 variant (G0/G1, G0/G2) had higher odds of CKD (OR 1.18, 95% CI 1.04-1.33) and FSGS (adjusted OR 1.61; 95% CI 1.04-2.48). Covariates did not modify the association of 1-2 APOL1 variants with CKD or FSGS.
Conclusion
Both monoallelic (G1/G0, G2/G0) and biallelic (G1/G1, G2/G2, G1/G2) risk variants have 18% and 25% higher odds of CKD, and 61% and 84% higher odds of FSGS, respectively. Individuals with monoallelic APOL1 variant should be classified as being at high risk for CKD and FSGS.
Funding
- NIDDK Support